Aarhus University Seal / Aarhus Universitets segl

Use of bisphosphonates in multiple myeloma patients in Denmark, 2005–2015

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Tina Bech Olesen, Aarhus University
  • ,
  • Ina Trolle Andersen
  • Anne Gulbech Ording, Aarhus University
  • ,
  • Vera Ehrenstein
  • Anouchka Seesaghur, Amgen Incorporated
  • ,
  • Carsten Helleberg, University of Copenhagen
  • ,
  • Trine Silkjær, Aarhus University
  • ,
  • Rohini K. Hernandez, Amgen Incorporated
  • ,
  • Daniela Niepel, Amgen Incorporated
  • ,
  • Niels Abildgaard, Haematology Research Unit, University of Southern Denmark

Purpose: To describe use of bisphosphonates in newly diagnosed multiple myeloma patients in Denmark. Methods: Using data from the Danish National Multiple Myeloma Registry, we conducted a population-based cohort study. Among patients newly diagnosed with multiple myeloma from 2005 to 2015, we examined use of bisphosphonates at first- and at progression/second-line anti-myeloma treatment overall, by patient characteristics, and myeloma complications. Results: Of 2947 patients starting first-line anti-myeloma treatment, 2207 patients (74.9%) received bisphosphonates. During a median follow-up of 27.6 (quartiles, 10.6–52.5) months, disease progression post-first-line treatment was recorded in 1546 patients, of whom 1065 (68.9%) were treated with bisphosphonates. Altogether, 80.9% of patients with and 37.6% of patients without myeloma bone disease were treated with bisphosphonates at first line and 73.0% and 42.7%, respectively, at progression/second line. Moreover, the proportion of patients treated with bisphosphonates decreased with increasing severity of renal impairment at first and at progression/second-line treatment. Conclusion: The proportion of patients treated with bisphosphonates as part of first- and second-line anti-myeloma treatment increased with presence of myeloma bone disease and decreased by presence and severity of renal impairment. Overall, 25% of newly diagnosed multiple myeloma patients had no record of bisphosphonate treatment, potentially indicating an unmet need.

Original languageEnglish
JournalSupportive Care in Cancer
Publication statusAccepted/In press - 2021

Bibliographical note

Funding Information:
This study was funded by an institutional research grant from Amgen Inc. to and administered by Aarhus University.

Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.

Copyright 2021 Elsevier B.V., All rights reserved.

    Research areas

  • Bisphosphonates, Epidemiology, Multiple myeloma

See relations at Aarhus University Citationformats

ID: 211497760